Drug Trial Radar · NCT02759419
A Long-term Extension Study of Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension.
Last checked: Nov 20, 2026Latest source record: Oct 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
18
Actual
Start
Jun 16, 2016
Primary completion
Sep 15, 2025
Study completion Sep 15, 2025
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- May 3, 2016
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To provide riociguat therapy to eligible patients with PAH originating from Bayer-sponsored trials with BAY63-2521/ Riociguat / Adempas® who are currently or recently treated in these trials until lack of patient benefit as assessed by investigator, or commercial availability and reimbursement.
Conditions
- Hypertension, Pulmonary
Interventions
Adempas (Riociguat, BAY63-2521)Drug
0.5 to 2.5 mg in 0.5 mg increments (according to individual adapted optimal dose determined in originating study) administered three times daily (tid)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of patients with treatment-emergent adverse events (TEAEs) as measure of safety and tolerabilityTime frame: Up to approx. 3 years
Locations
9 sites in 2 countries. Site status is shown where the registry gives one.
Site not named
Besançon, France
Site not named
Brest, France
Site not named
Le Kremlin-Bicêtre, France
Site not named
Lille, France
Site not named
Rouen, France
Site not named
Seoul, South Korea
Site not named
Seoul, Seoul Teugbyeolsi, South Korea
Site not named
Seoul, Seoul Teugbyeolsi, South Korea
Site not named
Seoul, Seoul Teugbyeolsi, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.